alexa Down Syndrome | United-kingdom | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Journals

Relevant Topics

Down Syndrome

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Down Syndrome

    Down syndrome (DS or DNS) or Down's syndrome and also known as trisomy 21, is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21. It is a genetic disorder. The parents of the affected individual are typically genetically normal. Down syndrome can be identified during pregnancy by prenatal screening followed by diagnostic testing, or after birth by direct observation and genetic testing. Since the introduction of screening, pregnancies with the diagnosis are often terminated. Regular screening for health problems common in Down syndrome is recommended throughout the person's life. Those who have one child with Down syndrome have about a 1% risk of having a second child with the syndrome, if both parents are found to have normal karyotypes. It is typically associated with physical growth delays, characteristic facial features, and mild to moderate intellectual disability. Education and proper care have been shown to improve quality of life. Some children with Down syndrome are educated in typical school classes, while others require more specialized education. Some individuals with Down syndrome graduate from high school and a few attend post-secondary education. In adulthood, about 20% in the United States do paid work in some capacity with many requiring a sheltered work environment.

  • Down Syndrome

    Support in financial and legal matters is often needed. Life expectancy is around 50 to 60 years in the developed world with proper health care. The average IQ of a young adult with Down syndrome is 50, equivalent to the mental age of an 8- or 9-year-old child, but this varies widely. Globally, as of 2010, Down syndrome occurs in about 1 per 1000 births and results in about 17,000 deaths. More children are born with Down syndrome in countries where abortion is not allowed and in countries where pregnancy more commonly occurs at a later age. About 1.4 per 1000 live births in the United States and 1.1 per 1000 live births in Norway are affected. In the 1950s, in the United States, it occurred in 2 per 1000 live births with the decrease since then due to prenatal screening and abortions. The number of pregnancies with Down syndrome is more than two times greater with many spontaneously aborting. It is the cause of 8% of all congenital disorders. Down syndrome is one of the most common chromosome abnormalities in humans, occurring in about one per 1000 babies born each year. In 2013 it resulted in 36,000 deaths down from 43,000 deaths in 1990. It is named after John Langdon Down, the British doctor who fully described the syndrome in 1866. Some aspects of the condition were described earlier by Jean-Étienne Dominique Esquirol in 1838 and Édouard Séguin in 1844.

  • Down Syndrome

    The genetic cause of Down syndrome—an extra copy of chromosome 21—was identified by French researchers in 1959. Maternal age affects the chances of having a pregnancy with Down syndrome. At age 20, the chance is one in 1441; at age 30, it is one in 959; at age 40, it is one in 84; and at age 50 it is one in 44. Although the probability increases with maternal age, 70% of children with Down syndrome are born to women 35 years of age and younger, because younger people have more children. The father's older age is also a risk factor in women older than 35, but not in women younger than 35, and may partly explain the increase in risk as women age. As it is a genetic disorder, consulting a doctor regularly is the only treatment. Utmost care should be taken to that patient. A group of medical specialists like Primary care pediatrician, Pediatric cardiologist, Pediatric gastroenterologist, Pediatric endocrinologist, Developmental pediatrician, Pediatric neurologist, Pediatric ear, nose and throat (ENT) specialist, Pediatric eye doctor (ophthalmologist), Audiologist, Physical therapist, Speech pathologist, and an Occupational therapist.

Expert PPTs

Speaker PPTs

  • Georgia Torres
    Effect of exercise intervention programs on anthropometric, physiological and cardiometabolic parameters of persons with and without metabolic syndrome
    PPT Version | PDF Version
  • Mandob Enyegue Damaris
    Prevalence of metabolic syndrome among University of Yaounde I campus police workers
    PPT Version | PDF Version
  • Danielle Venturini
    Increased oxidative stress according to number of risk factors in metabolic syndrome patients
    PPT Version | PDF Version
  • Thomas Boldicke
    Recent highlights of in vivo knockdown by intrabodies
    PPT Version | PDF Version
  • Laidoudi Aicha
    Acute renal failure and uveitis, which diagnosis is most likely in internal medicine? Tinu syndrome, through two observations
    PPT Version | PDF Version
  • Emanuele Corongiu
    Role of percutaneous tibial nerve stimulation in the treatment of neurogenic overactive bladder syndrome.
    PPT Version | PDF Version
  • Randhawa Ramanpreet
    Receiver Operating Characteristic curve analysis of Anthropometric Physiological and Biochemical indices and a comparison between four International definitions JSS, mATP-III, IDF and ATP-III for screening Metabolic Syndrome among Pre- and Postmenopausal Rural females of Amritsar (Punjab)
    PPT Version | PDF Version
  • Nisreen K Aref
    To compare serum leptin levels in obese women with polycystic ovary syndrome (PCOS) and normal ovulatory obese subjects in Saudi Arabia, and to evaluate the interrelationship between leptin concentration, sex hormones, and insulin resistance.
    PPT Version | PDF Version
  • Monica C Chuong
    Bioprocess Development Upstream and Downstream Technologies
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Elena Rampanelli
    Renal dysfunction and metabolic syndrome: the chicken or the egg?
    PPT Version | PDF Version
  • David Stejskal
    New marker of metabolic syndrome
    PPT Version | PDF Version
  • Vladimir Obolensky
    No-air-plasma currents and ozone therapy in treatment of patients with diabetic foot syndrome
    PPT Version | PDF Version
  • Wentao Zhou
    Patient centered transitional care for patients transferred from Intensive Care Unit (ICU) to step-down care unit: A mixed method study
    PPT Version | PDF Version
  • Kirill Shlyapnikov
    Fibromyalgia and chronic fatigue syndrome (CFS): translational biomarkers as applicable to monitor and to predict clinical manifestations
    PPT Version | PDF Version
  • Ljudmila Stojanovich
    The risk of thrombosis in patients with antiphospholipid syndrome: Influence of antiphospholipid antibody type and levels
    PPT Version | PDF Version
  • Tamer I Mahmoud
    Early Life Intervention Diminishes Manifestations of Sjögren's Syndrome in NOD.H-2h4 mice
    PPT Version | PDF Version
  • Calsolaro Valeria
    METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF THE ART AND DATA FROM A SECOND LEVEL OUTPATIENT CLINIC IN ITALY
    PPT Version | PDF Version
  • Roger W Beuerman
    Breaking down barriers to promote effective antibiotic action
    PPT Version | PDF Version
  • Mariana Artimos da Matta Tenorio
    Wilkie’s Syndrome: A Case Report
    PPT Version | PDF Version
  • Alex Constantinescu
    Strategies to minimize growth retardation in children with Steroid-sensitive nephrotic syndrome
    PPT Version | PDF Version
  • Irma Esther Del Moral Espinosa
    Effectiveness of combination prednisone tacrolimus compared with prednisone -cyclosporine in treatment steroid-resistant nephrotic syndrome
    PPT Version | PDF Version
  • Pupalan Iyngkaran
    Region Specific Cardiology Perspectives on the Cardiorenal Syndrome – Challenges and Solutions
    PPT Version | PDF Version
  • Sandra Rasmussen
    Live well: A recovery model for addiction and other reward deficiency syndrome
    PPT Version | PDF Version
  • Rafael Correa-Rocha
    HIV infection of Human regulatory T cells (Treg) downregulates Foxp3 expression and produces a loss of the suppressive capacity of these cells
    PPT Version | PDF Version
  • Emmanuel C. Besa
    New opportunities in a personalized approach to the preleukemic phase of myelodysplastic syndrome and acute myelogenous leukemia
    PPT Version | PDF Version
  • Amera Elzubier
    Lemierres syndrome: The forgotten disease? A case report
    PPT Version | PDF Version
  • Malgorzata Lipinska Gediga
    Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer ?
    PPT Version | PDF Version
  • Martha M Sklavos
    PDF Version
  • Tao Wu
    The association between TCM syndromes and SCAP polymorphisms insubjects with non-alcoholic fatty liver disease
    PPT Version | PDF Version
  • Galya Naydenova Atanasova
    Pulse pressure and apolipoprotein B/Apolipoprotein A1 in relation to the metabolic syndrome and its components
    PPT Version | PDF Version
  • Edward Rojas
    PDF Version
 

High Impact List of Articles

Conference Proceedings

adwords